Axiom Brain Health Appointed New Medical Director
Dr. Jeffery Greenberg has been named the new medical director at the Tampa research facility.
Updated on Oct. 5, 2026 in Alzheimer’s
The Global Alzheimer's Platform Foundation has named Dr. Jeffery Greenberg as the incoming medical director and principal investigator at Axiom Brain Health. He will succeed Dr. Susan Steen, who is scheduled to retire from her position at the end of 2026.
Why it matters
The leadership change ensures continuity for the Tampa-based research site, which manages a portfolio of Phase II-IV clinical trials. Dr. Steen is stepping down after three decades of providing care to the community.
Axiom Brain Health supports 15 research professionals within a 3,900-square-foot facility in Tampa. The center is part of a larger network comprising 76 clinical research sites globally.
The players
Dr. Jeffery Greenberg
He is the newly appointed medical director and principal investigator at Axiom Brain Health who previously spent 23 years in clinical practice in New Jersey.
Dr. Susan Steen
She is the outgoing medical director and principal investigator who has provided 40 years of medical contributions to the community.
Global Alzheimer's Platform Foundation
This is a health organization that owns and operates 76 clinical research sites, including the facility in Tampa.
Axiom Brain Health
This Tampa-based facility has provided care for 30 years and currently manages a portfolio of Phase II-IV clinical trials.
The details
Dr. Greenberg brings 23 years of clinical practice experience to the role and completed his residency at the Albert Einstein College of Medicine. He is currently working alongside Dr. Steen to facilitate a transition of leadership before her departure at the end of 2026.
Timeline
Axiom became a GAP owned-and-operated site in 2024.
The appointment of Dr. Jeffery Greenberg was announced on October 5, 2026.
Dr. Susan Steen is scheduled to retire at the end of 2026.
The Big Picture
The leadership change at Axiom follows the standard integration protocol established by the Global Alzheimer's Platform Foundation's clinical research network. This transition ensures that the local site remains aligned with the broader strategic objectives of the 76-site organization.
Patients currently enrolled in clinical trials at the Tampa facility will see a leadership transition over the coming months as Dr. Greenberg assumes his new responsibilities. This process is intended to maintain the continuity of care and the ongoing progress of the research trials.
The takeaway
Dr. Greenberg brings over two decades of clinical experience to his new role at the growing Tampa facility. The appointment marks a significant transition period as the organization prepares for long-term leadership changes by the end of 2026.
What happens next
The transition of site leadership at Axiom Brain Health is scheduled for completion by the end of 2026 when Dr. Steen officially retires.
Further reading
Learn more about local clinical research efforts on the Alzheimer’s section page.
